$7.70
1.79% day before yesterday
Nasdaq, Jul 11, 10:00 pm CET
ISIN
US2300311063
Symbol
CGEM
Sector
Industry

Cullinan Oncology Inc Stock price

$7.70
-1.28 14.25% 1M
-3.34 30.25% 6M
-4.48 36.78% YTD
-8.48 52.41% 1Y
-5.71 42.58% 3Y
-13.30 63.33% 5Y
-13.30 63.33% 10Y
-13.30 63.33% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.14 1.79%
ISIN
US2300311063
Symbol
CGEM
Sector
Industry

Key metrics

Basic
Market capitalization
$454.4m
Enterprise Value
$150.6m
Net debt
positive
Cash
$303.8m
Shares outstanding
58.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
0.8
Financial Health
Equity Ratio
94.9%
Return on Equity
-28.4%
ROCE
-37.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-208.6m | $-229.5m
EBIT
$-208.9m | $-233.4m
Net Income
$-178.7m | $-194.7m
Free Cash Flow
$-150.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-22.0% | -16.7%
EBIT
-21.9% | -18.5%
Net Income
-35.1% | -16.3%
Free Cash Flow
-23.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.0
FCF per Share
$-2.6
Short interest
11.7%
Employees
85
Rev per Employee
$0.0
Show more

Is Cullinan Oncology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Cullinan Oncology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Cullinan Oncology Inc forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a Cullinan Oncology Inc forecast:

Buy
94%
Hold
6%

Financial data from Cullinan Oncology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 55 55
25% 25%
-
- Research and Development Expense 154 154
21% 21%
-
-209 -209
22% 22%
-
- Depreciation and Amortization 0.31 0.31
3% 3%
-
EBIT (Operating Income) EBIT -209 -209
22% 22%
-
Net Profit -179 -179
35% 35%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cullinan Oncology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cullinan Oncology Inc Stock News

Neutral
GlobeNewsWire
about one month ago
Advances Cullinan's leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TCE in its pipeline
Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its management team will host a company event at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL and will participate in the Jefferies 2025 Global Hea...
More Cullinan Oncology Inc News

Company Profile

Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on 15 September, 2016 and is headquartered in Cambridge, MA.

Head office United States
CEO Nadim Ahmed
Employees 85
Founded 2016
Website cullinantherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today